Boston Pharmaceuticals Names Basson as Chief Medical Officer
5 February 2020 - - US-based Boston Pharmaceuticals has appointed Dr. Craig T. Basson, M.D., Ph.D., as chief medical officer, the company said.

Previously, Dr. Basson was Global Head of Translational Medicine (Cardiovascular and Metabolism) at Novartis for 10 years, where he led the team developing new global programmes to translate basic findings into novel therapeutics.

Dr. Basson was previously Global Head of Translational Medicine for the Cardiovascular and Metabolic Therapeutic Areas at Novartis Institutes for Biomedical Research.

At Novartis, he co-led the Cardiovascular Metabolism Disease Area Decision Board, oversaw a leadership of early clinical portfolio through Proof of Concept and supported late phase clinical programs by indication expansion PoC studies and specialised clinical pharmacology and profiling studies.

He has been involved in the development of a number of important and novel medicines for patients with cardiovascular disease, diabetes, and metabolic disorders.

Prior to Novartis, Dr. Basson was a Professor of Cardiology and Internal Medicine at Cornell University Medical College. He obtained an M.Sc. in Physiological Sciences at the University of Oxford and completed an M.D. and Ph.D. at Yale University. Dr. Basson serves as a scientific advisor to various for-profit and non-profit organisations.

Boston Pharmaceuticals is a clinical stage biopharmaceutical company that partners with innovative biotechnology and pharmaceutical companies to acquire drug development candidates.